Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

The application of discriminant analysis and Machine Learning methods as tools to identify and classify compounds with potential as transdermal enhancers.

Moss GP, Shah AJ, Adams RG, Davey N, Wilkinson SC, Pugh WJ, Sun Y.

Eur J Pharm Sci. 2012 Jan 23;45(1-2):116-27. doi: 10.1016/j.ejps.2011.10.027. Epub 2011 Nov 11.

PMID:
22101136
2.

Formulation and characterization of a captopril ethyl ester drug-in-adhesive-type patch for percutaneous absorption.

Gullick DR, Pugh WJ, Ingram MJ, Cox PA, Moss GP.

Drug Dev Ind Pharm. 2010 Aug;36(8):926-32. doi: 10.3109/03639040903585135.

PMID:
20184419
3.

The application of Gaussian processes in the prediction of percutaneous absorption.

Moss GP, Sun Y, Prapopoulou M, Davey N, Adams R, Pugh WJ, Brown MB.

J Pharm Pharmacol. 2009 Sep;61(9):1147-53. doi: 10.1211/jpp/61.09.0003.

PMID:
19703363
4.

Metabolism of captopril carboxyl ester derivatives for percutaneous absorption.

Gullick DR, Ingram MJ, Pugh WJ, Cox PA, Gard P, Smart JD, Moss GP.

J Pharm Pharmacol. 2009 Feb;61(2):159-65. doi: 10.1211/jpp/61.02.0004.

PMID:
19178762
5.

Transdermal delivery enhancement of haloperidol from gel formulations by 1,8-cineole.

Elgorashi AS, Heard CM, Niazy EM, Noureldin OH, Pugh WJ.

J Pharm Pharmacol. 2008 Jun;60(6):689-92. doi: 10.1211/jpp.60.6.0002.

PMID:
18498703
6.

Design, synthesis and characterization of captopril prodrugs for enhanced percutaneous absorption.

Moss GP, Gullick DR, Cox PA, Alexander C, Ingram MJ, Smart JD, Pugh WJ.

J Pharm Pharmacol. 2006 Feb;58(2):167-77.

PMID:
16451744
7.

Gastroretentive dosage forms: overview and special case of Helicobacter pylori.

Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F.

J Control Release. 2006 Mar 10;111(1-2):1-18. Epub 2006 Jan 5. Review.

PMID:
16403588
8.

Discriminant analysis as a tool to identify compounds with potential as transdermal enhancers.

Pugh WJ, Wong R, Falson F, Michniak BB, Moss GP.

J Pharm Pharmacol. 2005 Nov;57(11):1389-96.

PMID:
16259770
9.

Receptor regulatory properties evident in the molecular similarity of serotonin receptor ligands and purine nucleotides.

Williams WR, Pugh WJ, Nicholls PJ.

J Pharm Pharmacol. 2004 Dec;56(12):1563-72.

PMID:
15563764
10.

Topical delivery of retinyl ascorbate co-drug. 2. Comparative skin tissue and keratin binding studies.

Abdulmajed K, Heard CM, McGuigan C, Pugh WJ.

Skin Pharmacol Physiol. 2004 Nov-Dec;17(6):274-82.

PMID:
15528957
11.

Simple rules defining the potential of compounds for transdermal delivery or toxicity.

Magnusson BM, Pugh WJ, Roberts MS.

Pharm Res. 2004 Jun;21(6):1047-54.

PMID:
15212171
12.

Effect of vehicle pretreatment on the flux, retention, and diffusion of topically applied penetrants in vitro.

Rosado C, Cross SE, Pugh WJ, Roberts MS, Hadgraft J.

Pharm Res. 2003 Sep;20(9):1502-7.

PMID:
14567647
13.

Physico-chemical determinants of dermal drug delivery: effects of the number and substitution pattern of polar groups.

du Plessis J, Pugh WJ, Judefeind A, Hadgraft J.

Eur J Pharm Sci. 2002 Aug;16(3):107-12.

PMID:
12128163
14.

Receptor regulatory properties evident in the molecular similarity of dopamine receptor ligands and purine nucleotides.

Williams WR, Pugh WJ, Nicholls PJ.

J Pharm Pharmacol. 2002 May;54(5):671-9.

PMID:
12005362
15.

The effect of the nature of H-bonding groups on diffusion through PDMS membranes saturated with octanol and toluene.

Du Plessis J, Pugh WJ, Judefeind A, Hadgraft J.

Eur J Pharm Sci. 2002 Feb;15(1):63-9.

PMID:
11803132
16.
17.

The effect of hydrogen bonding on diffusion across model membranes: consideration of the number of H-bonding groups.

Du Plessis J, Pugh WJ, Judefeind A, Hadgraft J.

Eur J Pharm Sci. 2001 May;13(2):135-41.

PMID:
11297897
19.

The selection and design of topical and transdermal agents: a review.

Hadgraft J, Pugh WJ.

J Investig Dermatol Symp Proc. 1998 Aug;3(2):131-5. Review.

20.

Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions.

Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD.

Lett Appl Microbiol. 1997 Oct;25(4):279-83.

21.

Prostaglandin synthetase inhibitors in feverfew.

Pugh WJ, Sambo K.

J Pharm Pharmacol. 1988 Oct;40(10):743-5.

PMID:
2907548
22.

A relationship between foaming and H.L.B. value.

Badwan AA, Cham TM, James KC, Pugh WJ.

Int J Cosmet Sci. 1980 Feb;2(1):45-51. doi: 10.1111/j.1467-2494.1980.tb00233.x.

PMID:
19467079
23.

Preparation and characterisation of the C(10) to C(18) even-numbered triethanolamine alkyl sulphates.

Badwan AA, James KC, Pugh WJ.

Int J Cosmet Sci. 1980 Feb;2(1):39-44. doi: 10.1111/j.1467-2494.1980.tb00232.x.

PMID:
19467078
24.

The effect of surfactant purity on foam volume [proceedings].

Badwan AA, James KC, Pugh WJ.

J Pharm Pharmacol. 1979 Dec;31 Suppl:1P. No abstract available.

PMID:
42671
25.

Polarographic assay of glyceryl trinitrate by an internal standardization method.

Pugh WJ.

J Pharm Pharmacol. 1979 Jun;31(6):421-2. No abstract available.

PMID:
39152
26.

Disulphide cross-linked macromolecules formed by thiolated insulin and globin.

Etemad-Moghadam F, Mahbouba M, Pugh WJ, Smith HJ.

J Pharm Pharmacol. 1979 Mar;31(3):194-5. No abstract available.

PMID:
34704
27.

A relationship between foaming and HLB value [proceedings].

Badwan AA, James KC, Pugh WJ.

J Pharm Pharmacol. 1977 Dec;29 Suppl:22P. No abstract available.

PMID:
22651
28.

Disulphide cross-linking of thiolated alpha-chymotrypsin to form macromolecules.

Mahbouba M, Pugh WJ, Smith HJ.

J Pharm Pharmacol. 1974 Dec;26(12):952-5. No abstract available.

PMID:
4156860
29.

The micellar weights of the series dioctyl-to-didodecyl phosphatidylcholine.

Pugh WJ, Saunders L.

J Pharm Pharmacol. 1974 Apr;26(4):286-8. No abstract available.

PMID:
4151391
30.

A laser light scattering apparatus.

Pugh WJ, Saunders L.

J Pharm Pharmacol. 1971 Dec;23:85S-88S. No abstract available.

PMID:
4401534

Supplemental Content

Support Center